| Development sample Bristol and Birmingham n = 16,527 | Validation sample Wolverhampton n = 4,468 | ||||||
---|---|---|---|---|---|---|---|---|
 | Any-stage AKI | Stage-3 AKI | Any-stage AKI | Stage-3 AKI | ||||
Hosmer-Lemeshow P -values a | P | P | P | P | ||||
Initial model (P <0.001) | 0.490 | 0.001 | 0.192 | <0.001 | ||||
More inclusive model (P <0.05) | 0.784 | <0.001 | 0.406 | <0.001 | ||||
Euroscore | <0.001 | <0.001 | 0.333 | <0.001 | ||||
Cleveland clinic | 0.112 | <0.001 | 0.141 | <0.001 | ||||
Metha score | 0.009 | <0.001 | 0.136 | <0.001 | ||||
Ng score | 0.013 | <0.001 | 0.174 | <0.001 | ||||
 | Any-stage AKI | Stage-3 AKI | Any-stage AKI | Stage-3 AKI | ||||
Slope and intercept b | Slope | Intercept | Slope | Intercept | Slope | Intercept | Slope | Intercept |
Initial model (P <0.001) | 1.045 | -0.007 | 1.094 | -0.002 | 1.152 | -0.009 | 1.529 | 0.009 |
More inclusive model (P <0.05) | 1.050 | -0.008 | 1.334 | -0.007 | 1.140 | -0.001 | 2.088 | -0.003 |
Euroscore | 1.050 | -0.009 | 1.145 | -0.004 | 1.152 | -0.038 | 1.789 | -0.016 |
Cleveland clinic | 1.283 | -0.048 | 1.145 | -0.004 | 1.927 | -0.138 | 3.376 | -0.033 |
Metha score | 1.144 | -0.029 | 1.513 | -0.013 | 1.348 | -0.040 | 2.199 | -0.010 |
Ng score | 1.130 | -0.021 | 1.378 | -0.008 | 1.338 | -0.010 | 2.196 | -0.004 |